Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Dicerna Pharmaceuticals Inc (DRNA) USD0.0001

Sell:$29.00 Buy:$29.02 Change: $0.51 (1.73%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
Change: $0.51 (1.73%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
Change: $0.51 (1.73%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.

Contact details

75 Hayden Avenue
United States
+1 (617) 6218097

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.21 billion
Shares in issue:
76.32 million
United States
US dollar

Key personnel

  • J. Kevin Buchi
    Independent Chairman of the Board
  • Douglas Fambrough
    President, Chief Executive Officer, Director
  • Douglas Pagan
    Chief Financial Officer
  • James Weissman
    Chief Operating Officer, Executive Vice President
  • Bob Brown
    Executive Vice President, Research and Development, Chief Scientific Officer
  • Shreeram Aradhye
    Executive Vice President, Chief Medical Officer
  • Robert Ciappenelli
    Chief Commercial Officer
  • Ling Zeng
    Chief Legal Officer and Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.